Thursday Evening Activities

State of SITC: Membership Business Meeting

The State of SITC: Membership Business Meeting has been moved to Thursday evening, November 7, at 5:30 pm immediately following the conclusion of the SITC Workshop on Cancer Immunotherapy and the SITC Primer on Tumor Immunology and Cancer Immunotherapy™. This meeting will give a general update of the current activities of the Society, provide the year in review, and highlight initiatives moving forward. The meeting is open to all SITC 2013 attendees and will be followed by the SITC Welcome Reception!

Welcome Reception Featuring Speed Networking

Welcome Reception

The SITC Welcome Reception is a new event this year and is the official kick off to SITC's 28th Annual Meeting! This event is free of charge to anyone registered for the Annual Meeting, and Workshop and Primer attendees are welcome to attend for a nominal fee. This reception will provide a relaxing opportunity to both network with old friends and meet new acquaintances.

Speed Networking

As part of this year's Welcome Reception, SITC is also featuring the opportunity for attendees to participate in an optional Speed Networking event. Made up of a series of one-on-one mini-meetings, participants have the opportunity to gain a better understanding of recent developments in cancer immunotherapy, identify common interests, strike up potential research collaborations and establish relationships with various stakeholders in the field - all in one setting.

Once again, participation in the "Speed Networking" portion of the Welcome Reception is optional and preregistration is requested on the registration form.

SITC Quick Links

Program presentations are now available through the "schedule" section of individual programs!

Connect with SITC!

Support Information

Thank you to all SITC 2013 supporters!

Confirm your support for SITC's 2014 programs today! Click here for more information.

Annual Meeting Supporters

Platinum

Gold

Silver

Genentech
Janssen
MedImmune
Prometheus Laboratories

Bronze

Amgen
Celgene Corporation
Provectus Pharmaceuticals

Copper

Argos Therapeutics

Center for Cancer Research
National Cancer Institute
National Institutes of Health
Department of Health and Human Services

Immuneering Corporation

Lonza Walkersville

Oncothyreon

Prima BioMed